Time on boards
- Boards served
- 3
- Current seats
- 3
- Board service
- 6 years
- Director since
- 2023
6 years of board service in total across 3 boards, counting each seat separately. Longest: Karyopharm Therapeutics Inc., 3 years.
Karyopharm Therapeutics Inc.
Director
Mereo BioPharma Group plc
Director
Freenome Inc.
Director
Insider trades
All notable trades →From SEC Forms 4 and 5. Open-market purchases and sales are highlighted; grants, option exercises and shares withheld for tax are routine.
| Date | Company | Transaction | Shares | Price | Value |
|---|---|---|---|---|---|
| May 21, 2026 | Karyopharm Therapeutics Inc. | Grant or award | +15,508 | — | — |
| Aug 22, 2024 | Mereo BioPharma Group plc | Option exercise | +1,825 | $3.00 | $5,475 |
| Aug 22, 2024 | Mereo BioPharma Group plc | Option exercise | +6,492 | $1.84 | $11,945 |
| Aug 22, 2024 | Mereo BioPharma Group plc | Option exercise | +12,418 | $2.72 | $33,777 |
| Aug 22, 2024 | Mereo BioPharma Group plc | Option exercise | +38,953 | $1.31 | $51,028 |
| Aug 22, 2024 | Mereo BioPharma Group plc | Option exercise | +43,485 | $0.94 | $40,876 |
| Aug 22, 2024 | Mereo BioPharma Group plc | Option exercise | +2,071 | $3.87 | $8,015 |
| Aug 22, 2024 | Mereo BioPharma Group plc | Open-market sale | −105,244 | $4.43 | $466,231 |
| Jun 7, 2024 | Karyopharm Therapeutics Inc. | Open-market sale | −229,308 | $0.95 | $217,843 |
| Jun 7, 2024 | Karyopharm Therapeutics Inc. | Open-market sale | −2,240 | $0.95 | $2,128 |
| Jun 6, 2024 | Karyopharm Therapeutics Inc. | Open-market sale | −117,307 | $0.98 | $114,961 |
| Jun 6, 2024 | Karyopharm Therapeutics Inc. | Open-market sale | −1,145 | $0.98 | $1,122 |
| Jun 5, 2024 | Karyopharm Therapeutics Inc. | Open-market sale | −463,518 | $0.96 | $444,977 |
| Jun 5, 2024 | Karyopharm Therapeutics Inc. | Open-market sale | −4,526 | $0.96 | $4,345 |
| Jun 4, 2024 | Karyopharm Therapeutics Inc. | Open-market sale | −337,742 | $0.95 | $320,855 |
Reviews (0)
Sign in to write a review.
No reviews yet. Be the first to write one.